We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Retain Molina Healthcare Stock for Now
Read MoreHide Full Article
Key Takeaways
Molina Healthcare benefits from Medicaid contracts, Medicare Duals growth and recent contract wins.
Molina Healthcare expects its G&A ratio to improve to 6.4% in 2026 from 6.6% in 2025.
MOH faces elevated medical costs, while its forward P/E exceeds both industry and five-year median levels.
Molina Healthcare, Inc. (MOH - Free Report) is well-positioned for growth, supported by contract wins, strategic acquisitions and solid cash generation capacity. The company operates in three segments: Medicaid, Medicare and Marketplace. Over the past six months, MOH stock has gained 32.9% compared with the industry’s 31.8% growth.
MOH – with a market cap of $10.6 billion — offers health insurance plans sponsored by the government for individuals and families. It focuses on delivering affordable and comprehensive coverage, especially for lower-income people.
Courtesy of solid prospects, MOH currently carries a Zacks Rank #3 (Hold) and a Value Score of B.
Where Do Estimates for MOH Stand?
The Zacks Consensus Estimate for Molina Healthcare’s 2026 earnings is pegged at $5.29 per share. In the past 30 days, it has witnessed one upward estimate revision against none in the opposite direction. The consensus estimate for revenues is pegged at $44.5 billion for 2026. The 2027 revenue estimate is pegged at $48 billion, indicating a 7.9% year-over-year increase.
It beat earnings estimates in two of the past four quarters and missed twice.
Molina Healthcare, Inc Price, Consensus and EPS Surprise
An aging U.S. population is supporting long-term demand for government-sponsored healthcare coverage, particularly Medicare and dual-eligible plans. This creates a favorable backdrop for Molina Healthcare’s Medicare Duals business, which is becoming an increasingly important part of its portfolio. Medicare Duals delivered a second-quarter 2026 MCR of 90.7%, while the full-year MCR outlook was lowered to 92.2%. The business is also benefiting from $2 billion of MMP premium being converted into new products and incremental premium from recent contract wins.
Rising healthcare needs among low-income and dual-eligible populations are creating opportunities in Medicaid and integrated care. Molina Healthcare continues to expand through state Medicaid contracts and integrated duals offerings, with the renewal of its Wisconsin contract providing additional room to grow in the latter. The company also retained its $2 billion Illinois Managed Medicaid contract, reinforcing its presence in a major Medicaid market. Beyond organic growth, MOH has an active acquisition pipeline and plans to deploy capital toward accretive deals, supporting its longer-term goal.
Molina Healthcare continues to emphasize operating efficiency through its long-running restructuring and profitability initiatives. These efforts have steadily lowered its adjusted G&A ratio, which improved from 7.2% in 2023 to 6.7% in 2024 and further to 6.6% in 2025. Looking ahead, the company expects its full-year 2026 G&A ratio to improve to 6.4%.
MOH's balance sheet strength provides financial flexibility. Its cash and cash equivalents of $5 billion at the end of the second quarter of 2026 were much higher than the long-term debt of $3.8 billion. Operating cash inflow was $788 million in the first six months of 2026 against an outflow of $112 million in the prior-year period.
Risks for MOH Stock
There are some factors, however, that investors should keep a careful eye on.
Molina Healthcare continues to face pressure from elevated medical costs, with its consolidated MCR rising to 91.6% in the first half of 2026 from 89.8% a year ago. Management also expects Medicaid MCR to remain elevated through 2026, which could weigh on margin recovery.
MOH trades at a premium valuation, with a forward P/E of 24.45X compared with the industry average of 16.13X and its five-year median of 14.69X. The stretched valuation may limit upside potential if earnings growth remains under pressure.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.82 per share has witnessed six upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.3 billion, suggesting 18.2% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past 30 days, against no movement in the opposite direction. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed nine upward revisions in the past 30 days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why Investors Should Retain Molina Healthcare Stock for Now
Key Takeaways
Molina Healthcare, Inc. (MOH - Free Report) is well-positioned for growth, supported by contract wins, strategic acquisitions and solid cash generation capacity. The company operates in three segments: Medicaid, Medicare and Marketplace. Over the past six months, MOH stock has gained 32.9% compared with the industry’s 31.8% growth.
MOH – with a market cap of $10.6 billion — offers health insurance plans sponsored by the government for individuals and families. It focuses on delivering affordable and comprehensive coverage, especially for lower-income people.
Courtesy of solid prospects, MOH currently carries a Zacks Rank #3 (Hold) and a Value Score of B.
Where Do Estimates for MOH Stand?
The Zacks Consensus Estimate for Molina Healthcare’s 2026 earnings is pegged at $5.29 per share. In the past 30 days, it has witnessed one upward estimate revision against none in the opposite direction. The consensus estimate for revenues is pegged at $44.5 billion for 2026. The 2027 revenue estimate is pegged at $48 billion, indicating a 7.9% year-over-year increase.
It beat earnings estimates in two of the past four quarters and missed twice.
Molina Healthcare, Inc Price, Consensus and EPS Surprise
Molina Healthcare, Inc price-consensus-eps-surprise-chart | Molina Healthcare, Inc Quote
MOH’s Growth Drivers
An aging U.S. population is supporting long-term demand for government-sponsored healthcare coverage, particularly Medicare and dual-eligible plans. This creates a favorable backdrop for Molina Healthcare’s Medicare Duals business, which is becoming an increasingly important part of its portfolio. Medicare Duals delivered a second-quarter 2026 MCR of 90.7%, while the full-year MCR outlook was lowered to 92.2%. The business is also benefiting from $2 billion of MMP premium being converted into new products and incremental premium from recent contract wins.
Rising healthcare needs among low-income and dual-eligible populations are creating opportunities in Medicaid and integrated care. Molina Healthcare continues to expand through state Medicaid contracts and integrated duals offerings, with the renewal of its Wisconsin contract providing additional room to grow in the latter. The company also retained its $2 billion Illinois Managed Medicaid contract, reinforcing its presence in a major Medicaid market. Beyond organic growth, MOH has an active acquisition pipeline and plans to deploy capital toward accretive deals, supporting its longer-term goal.
Molina Healthcare continues to emphasize operating efficiency through its long-running restructuring and profitability initiatives. These efforts have steadily lowered its adjusted G&A ratio, which improved from 7.2% in 2023 to 6.7% in 2024 and further to 6.6% in 2025. Looking ahead, the company expects its full-year 2026 G&A ratio to improve to 6.4%.
MOH's balance sheet strength provides financial flexibility. Its cash and cash equivalents of $5 billion at the end of the second quarter of 2026 were much higher than the long-term debt of $3.8 billion. Operating cash inflow was $788 million in the first six months of 2026 against an outflow of $112 million in the prior-year period.
Risks for MOH Stock
There are some factors, however, that investors should keep a careful eye on.
Molina Healthcare continues to face pressure from elevated medical costs, with its consolidated MCR rising to 91.6% in the first half of 2026 from 89.8% a year ago. Management also expects Medicaid MCR to remain elevated through 2026, which could weigh on margin recovery.
MOH trades at a premium valuation, with a forward P/E of 24.45X compared with the industry average of 16.13X and its five-year median of 14.69X. The stretched valuation may limit upside potential if earnings growth remains under pressure.
Stocks to Consider
Some better-ranked stocks in the Medical space are BrightSpring Health Services, Inc. (BTSG - Free Report) , Globus Medical, Inc. (GMED - Free Report) and Centene Corporation (CNC - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for BrightSpring Health Services’ current-year earnings of $1.82 per share has witnessed six upward revisions in the past 30 days against no movement in the opposite direction. BTSG beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 16.1%. The consensus estimate for current-year revenues is pegged at $15.3 billion, suggesting 18.2% year-over-year growth.
The Zacks Consensus Estimate for Globus Medical’s current-year earnings of $4.93 per share has witnessed three upward revisions in the past 30 days, against no movement in the opposite direction. GMED beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.9%. The consensus estimate for current-year revenues is pegged at $3.2 billion, suggesting 8.8% year-over-year growth.
The Zacks Consensus Estimate for Centene’s current-year earnings of $4.89 per share has witnessed nine upward revisions in the past 30 days, against no movement in the opposite direction. CNC beat earnings estimates in each of the trailing four quarters, with an average surprise of 151.3%. The consensus estimate for current-year revenues is pegged at $196.3 billion, suggesting 0.8% year-over-year growth.